CN116179419A - Lactobacillus plantarum with lipid-lowering function and application thereof - Google Patents
Lactobacillus plantarum with lipid-lowering function and application thereof Download PDFInfo
- Publication number
- CN116179419A CN116179419A CN202211609647.5A CN202211609647A CN116179419A CN 116179419 A CN116179419 A CN 116179419A CN 202211609647 A CN202211609647 A CN 202211609647A CN 116179419 A CN116179419 A CN 116179419A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- lipid
- sdj09
- bacteria
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 56
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 56
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 56
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 33
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 16
- 239000002207 metabolite Substances 0.000 claims abstract description 15
- 102000019280 Pancreatic lipases Human genes 0.000 claims abstract description 10
- 108050006759 Pancreatic lipases Proteins 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 10
- 229940116369 pancreatic lipase Drugs 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 230000006372 lipid accumulation Effects 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 244000005700 microbiome Species 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 37
- 239000001963 growth medium Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 210000001789 adipocyte Anatomy 0.000 claims description 5
- 238000009630 liquid culture Methods 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 7
- 239000012530 fluid Substances 0.000 abstract description 11
- 239000006041 probiotic Substances 0.000 abstract description 11
- 235000018291 probiotics Nutrition 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000002496 gastric effect Effects 0.000 abstract description 9
- 230000001603 reducing effect Effects 0.000 abstract description 9
- 208000008589 Obesity Diseases 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 8
- 235000020824 obesity Nutrition 0.000 abstract description 8
- 239000002253 acid Substances 0.000 abstract description 7
- 241001052560 Thallis Species 0.000 abstract description 4
- 239000003833 bile salt Substances 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 3
- DGOBMKYRQHEFGQ-UHFFFAOYSA-L acid green 5 Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 DGOBMKYRQHEFGQ-UHFFFAOYSA-L 0.000 abstract 1
- 244000013123 dwarf bean Species 0.000 abstract 1
- 235000021331 green beans Nutrition 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- 239000008055 phosphate buffer solution Substances 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 13
- 241000186660 Lactobacillus Species 0.000 description 12
- 229940039696 lactobacillus Drugs 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- -1 4-nitrooctanoic acid phenyl ester Chemical compound 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Fodder In General (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses lactobacillus plantarum with a lipid-lowering function and application thereof, and belongs to the field of microbial application. The strain has been deposited at the collection of microorganism strains of Guangdong province at 1 month 14 of 2022 under the accession number GDMCC No:62211. the lactobacillus plantarum SDJ09 is separated from the acid green beans, has cholesterol reducing capability and pancreatic lipase inhibiting capability, has strong adhesiveness, excellent probiotics characteristics (acid resistance and bile salt resistance, gastric intestinal fluid simulating characteristic in vitro and antibacterial capability) and safety, and can reduce lipid accumulation in 3T3-L1adipocytes by cell-free extracts, metabolites and inactivated thalli. The characteristics of the lactobacillus plantarum SDJ09 lead the lactobacillus plantarum SDJ09 to have wide application prospect, can be applied to health-care foods, medicines and animal feeds with lipid-lowering functions, and provides a new way for preventing and treating body obesity.
Description
Technical Field
The invention relates to the field of microorganism application, in particular to lactobacillus plantarum with a lipid-lowering function and application thereof.
Background
With the gradual rise of the incidence of obesity, obesity has become a global public problem, leading to reduced quality of life for obese people and even affecting life expectancy. Obesity is also closely related to the occurrence of metabolic syndrome such as nonalcoholic fatty liver disease, type II diabetes, hyperlipidemia, atherosclerosis, etc. The current treatment of obesity is very challenging, the most common drug on the market is orlistat, but the most common drug still has side effects such as oily stool and gastrointestinal discomfort, so the development of more effective and safer anti-obesity drugs becomes a research hotspot.
Probiotics are known as living microorganisms and can exert beneficial effects on the body in certain amounts. Lactobacillus and bifidobacteria are the most common species in probiotic preparations, as their various beneficial effects on body health have been used for the prevention and treatment of various medical diseases and are the focus of next generation probiotic research. The research shows that lactobacillus can maintain the dynamic balance of intestinal flora of organism, strengthen organism immunity, and has the beneficial effects of anti-inflammatory, anti-tumor, blood sugar reducing, serum cholesterol reducing, etc., and the scholars can find that lactobacillus can influence the metabolism of cholesterol in human body in seventies early 20 th century, and then the related research proves the cholesterol reducing effect of lactobacillus.
Lactic acid bacteria have been demonstrated in several studies to have beneficial effects on reducing obesity, and their anti-obesity effects are different not only between strains, but also between inactivated bacteria and live bacteria, and between single bacteria and mixed bacteria. The study of anti-obesity effects is also not limited to strain levels but extends to their byproducts including probiotic metabolites, functional proteins, cell lysates, short chain fatty acids, and the like. The inactivated probiotics have the characteristics of wider application, stability and safety, and the application of the probiotics is not limited by low-temperature yoghurt, and the probiotics can be applied to foods under a high-temperature process. In order to expand the application range of probiotics, the invention provides a novel bacterial strain with probiotic characteristics of living bacteria, metabolic products thereof, cell-free extracts and inactivated bacteria.
Disclosure of Invention
The invention aims to provide lactobacillus plantarum with lipid-lowering function and application thereof, so as to solve the problems in the prior art, and the live bacteria, cell-free extract, metabolite and inactivated bacteria of the strain can reduce lipid accumulation in fat cells, have wide application prospect and provide a new way for preventing and treating body obesity.
In order to achieve the above object, the present invention provides the following solutions:
the invention provides lactobacillus plantarum (Lactobacillus plantarum) SDJ09 with lipid-lowering function, which is preserved in the microorganism strain preservation center of Guangdong province at 1 month 14 of 2022, wherein the preservation number is GDMCC No:62211.
the invention also provides a preparation which comprises the lactobacillus plantarum.
Further, one or more of a live bacterium, an inactivated bacterium, a metabolite, and a cell-free extract comprising the lactobacillus plantarum.
Further, the preparation method of the living bacteria comprises the following steps:
inoculating the lactobacillus plantarum into MRS liquid culture medium for culture, and then regulating the strain concentration to 10 8 -10 9 CFU/mL.
Further, sterilizing the live bacteria at high temperature to obtain inactivated bacteria; performing ultrasonic treatment on the living bacteria, and centrifuging to obtain supernatant to obtain a cell-free extract; centrifuging the living bacteria to obtain supernatant, and filtering to obtain the metabolite.
Further, the inoculation amount of the lactobacillus plantarum is 2-3%; the culture conditions are as follows: culturing at 35-38deg.C for 24-36 hr.
Further, the high-temperature sterilization specifically comprises the following steps: sterilizing at 110-150deg.C for 10-30min; the power of the ultrasonic treatment is 200-300W, and the time is 20-30min.
The invention also provides an application of the lactobacillus plantarum or the preparation in preparing lipid-lowering foods, medicines or animal feeds.
Further, the lactobacillus plantarum or the preparation plays a role in reducing lipid by degrading cholesterol, inhibiting pancreatic lipase and reducing lipid accumulation in fat cells.
The invention also provides a food, medicine or animal feed with the lipid-lowering function, which comprises the lactobacillus plantarum or the preparation.
The invention discloses the following technical effects:
the invention provides lactobacillus plantarum (Lactobacillus plantarum) GXSDJ09 (called lactobacillus plantarum SDJ09 for short) separated from a kidney bean, which has cholesterol reducing capability and pancreatic lipase inhibiting capability, has stronger adhesiveness and excellent probiotic characteristics (acid and bile salt resisting property, gastric and intestinal fluid simulating property in vitro and antibacterial capability) and safety, and can reduce lipid accumulation in 3T3-L1adipocytes. The characteristics of the lactobacillus plantarum SDJ09 lead the lactobacillus plantarum SDJ09 to have wide application prospect, can be applied to health-care foods, medicines and animal feeds with lipid-lowering functions, and provides a new way for preventing and treating body obesity.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 shows a cholesterol standard curve and the in vitro cholesterol degradation rate of 39 lactic acid bacteria;
FIG. 2 is a gel electrophoresis diagram of the PCR products of Lactobacillus plantarum SDJ09 strain and a constructed development tree;
FIG. 3 shows the growth curve and the acidogenesis curve of Lactobacillus plantarum SDJ 09;
FIG. 4 is a chart of oil red O staining of 3T3-L1adipocytes under different treatment conditions, A is a model set, B is a cell-free extract treatment set, C is a metabolite treatment set, and D is an inactivated thallus treatment set;
FIG. 5 is the effect of different components of Lactobacillus plantarum SDJ09 on triglycerides in 3T3-L1 adipocytes; * Represents that the model group was significantly different from the normal group (P < 0.05), and # represents that the different treatment groups were significantly different from the model group (P < 0.05).
Detailed Description
Various exemplary embodiments of the invention will now be described in detail, which should not be considered as limiting the invention, but rather as more detailed descriptions of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In addition, for numerical ranges in this disclosure, it is understood that each intermediate value between the upper and lower limits of the ranges is also specifically disclosed. Every smaller range between any stated value or stated range, and any other stated value or intermediate value within the stated range, is also encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the invention described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from consideration of the specification of the present invention. The specification and examples of the present invention are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are intended to be inclusive and mean an inclusion, but not limited to.
1. Separation and purification of lactic acid bacteria
10 traditional special fermented foods (pickled peppers, pickled Chinese cabbages, milk fans, ham, sour soup, chilli sauce, sour beans, sour bamboo shoots, pickle and soybean paste) are taken as samples from four areas of Sichuan, yunnan, guizhou and Guangxi, 25g of the samples are taken, the samples are put into 225mL of sterile physiological saline, the shaking is carried out for 30min, 200 mu L of diluent is absorbed by gradient dilution and coated on MRS screening solid culture medium, and the culture is carried out for 48h at the constant temperature of 37 ℃. The bacterial colony is selected on a flat plate, the bacterial colony is mostly in a central protruding form and is white in color, a obvious calcium dissolving ring is arranged around the bacterial colony, the edge of the bacterial colony is tidy, the surface of the bacterial colony is moist and opaque, the bacterial strain is accompanied with sour taste, the bacterial colony is subjected to continuous purification culture for 3 times, a single bacterial colony is selected for carrying out a catalase experiment and a gram staining experiment (experimental method reference 'screening and application research of antioxidant function lactobacillus in chopped capsicum'), the bacterial strain which is gram-positive and rod-shaped and has no spore, the bacterial strain is single in form and negative to the catalase is selected, and glycerol is preserved at the temperature of minus 20 ℃ for later use. The 39 strains of lactic acid bacteria are obtained by separation and purification through the method.
2. Screening of Lactobacillus plantarum SDJ09
2.1 screening of cholesterol-lowering lactic acid bacteria
Drawing a cholesterol standard curve: cholesterol stock solutions of 0.1, 0.2, 0.3, 0.4, 0.5 and 0.6mL are respectively taken in a clean test tube, nitrogen is blown at 60 ℃ to evaporate the liquid, phthalic aldehyde and concentrated sulfuric acid are sequentially added to be uniformly mixed, the absorbance is measured at 550nm after standing, and a standard curve is drawn (the upper graph in figure 1).
After the 39 strains are respectively subjected to seed MRS culture medium, inoculating the strains into the MRS culture medium containing cholesterol according to the inoculum size of 3 percent, culturing the strains at the constant temperature of 37 ℃ for 36 hours, centrifuging the strains for 10 minutes under the condition of 8000r/min, and measuring the cholesterol degradation capacity by adopting a phthalic dicarboxaldehyde method, wherein the operation steps are as follows: taking 1mL of supernatant in a test tube, adding 4mL of 95% ethanol, 3mL of 33% KOH, water bath at 60 ℃ for 15min, adding 5mL of n-hexane and 4mL of distilled water, fully oscillating, standing and layering, taking 3mL of supernatant in a small test tube, blowing nitrogen at 60 ℃ to evaporate the reagent, adding 5mL of phthalic dicarboxaldehyde and 3mL of concentrated sulfuric acid, fully mixing uniformly, detecting the light absorption value at the wavelength of 550nm, calculating the cholesterol removal rate according to a formula, repeating the experiment for five times and averaging.
Cholesterol degradation rate= (blank OD 550 Experimental group OD 550 ) Blank OD 550 x100％。
The results of the cholesterol degradation rate experiments of 39 lactic acid bacteria are shown in the lower graph of FIG. 1, and thus 5 lactic acid bacteria strains SDJ07, SDJ09, SS08, SDJ13 and SS05 having high cholesterol-lowering ability are obtained to participate in the following experiments.
2.2 determination of pancreatic Lipase inhibition Rate
The operation steps of the pancreatic lipase inhibition rate of the 5 strains are as follows: after the strain was inoculated into MRS medium at an inoculum size of 3% for 18 hours, it was washed twice with PBS having pH=7.2, resuspended in PBS, and OD was adjusted 600 To 0.5+ -0.02 (10) 8 -10 9 CFU/mL). Tris-HCl buffer solution of pH=8.5 was prepared, 12.5. Mu.L of 5mM 4-nitrooctanoic acid phenyl ester (NPC) was added to 500. Mu.L of Tris-HCl buffer solution and mixed with 125. Mu.L of bacterial solution, 12.5. Mu.L of pancreatic lipase (5 mg/mL Tris-HCl buffer solution) was further added and mixed for 2 minutes, and the mixture was incubated at 37℃for 30 minutes, 150. Mu.L of the mixture was taken in a 96-well plate, and absorbance (n=3) was measured at a wavelength of 412 nm. Wherein the sample blank is dimethyl sulfoxide (DMSO) instead of NPC, the control sample is NPC only without lactobacillus, and the blank is DMSO instead of NPC without lactobacillus. The inhibition was calculated according to the following formula:
pancreatic lipase inhibition (%) =1- ((C-C0)/(N-N0)) ×100%
Wherein: c0 represents the OD value of the sample blank set at the wavelength 412nm, C represents the OD value of the sample at the wavelength 412nm, N0 represents the OD value of the control sample blank set at the wavelength 412nm, and N represents the OD value of the control sample at the wavelength 412 nm. The experimental results are shown in Table 1.
Table 15 pancreatic lipase inhibition ratio by lactic acid bacteria
2.3 adhesion test
HT-29 cells were completely cultured with 1640 containing 10% fetal bovine serum based on 37℃and 5% CO using Lactobacillus rhamnosus LGG as control 2 Culturing under the condition, digesting with 0.25% pancreatin, diluting with 1640 complete culture medium without double antibody, and adjusting cell number to 2×10 5 culturing cell/mL in a 24-hole plate with 0.5mL until proliferation and fusion are 80%, washing cells with sterile PB, adding bacterial liquid to be detected, incubating for 2 hours, washing cells with PBS, adding pancreatin for digestion for 2min to terminate reaction, adding 1mL 0.05%TritionX-100, repeatedly blowing to completely lyse the cells, standing for 5min, transferring the lysate into a sterile test tube, diluting and coating, and calculating adhesiveness according to the following formula:
adhesion = (total number of adherent bacteria/number of HT-29 cells per dish) x100%;
the experimental results are shown in table 2:
table 2 6 adhesion test of lactic acid bacteria
And (3) screening out strains with higher cholesterol reducing capacity, higher pancreatic lipase inhibition rate and highest adhesiveness by combining the experimental results: SDJ09, a strain isolated from a market in carob, guangxi.
3. 16S rRNA Gene sequence analysis
Carrying out PCR identification on the screened strain, extracting strain genome DNA by using a bacterial DNA extraction kit, and carrying out gene amplification on the strain by using universal primers 27F and 1492R, wherein the amplification conditions are as follows: pre-denaturation at 94℃for 3min, denaturation at 94℃for 30s, annealing at 55℃for 30s, extension at 72℃for 1min, circulation for 30 times, extension at 72℃for 5min, and preservation at 4 ℃. After analysis of the PCR products by 1% agarose gel electrophoresis (upper panel in FIG. 2), they were sent to Shanghai bioengineering company for sequencing, the 16S rRNA gene sequences were aligned in NCBI, homology analysis was performed by BLAST, and development tree establishment was performed by MEGA 5.0 software (lower panel in FIG. 2). The identification shows that SDJ09 is lactobacillus plantarum, named lactobacillus plantarum (Lactobacillus plantarum) GXSDJ09 (abbreviated as lactobacillus plantarum SDJ 09) and stored in the Guangdong province microorganism strain collection center, and the storage address is: the collection date is 2022, 1 month and 14 days, and the collection number is GDMCCNo:62211.
4. probiotic properties of lipid-lowering lactic acid bacteria
4.1 growth curve and acid production curve of Lactobacillus plantarum SDJ09
The strain is inoculated into MRS liquid culture medium according to 3% inoculum size, and is subjected to stationary culture at 37 ℃ and sampling every 2 hours, the absorbance value and pH value of fermentation liquor at 600nm are measured, and then a growth curve and an acidogenic curve are drawn. The experimental results are shown in figure 3, and lactobacillus plantarum SDJ09 has excellent growth performance and acid production capacity.
4.2 acid and bile salt resistance
After picking single colony to culture in MRS liquid culture medium for 20h, centrifuging at 4deg.C for 10min at 8000r/min, re-suspending with sterile PBS, and adjusting OD 600 Until 0.5+ -0.02, and then 3% of the inoculation amount was inoculated into MRS liquid medium with pH=2 and 0.3% of ox gall salt, respectively, dilution coating was performed at 0, 2 and 3 hours, and the survival rate was measured by counting viable bacteria on plates before and after treatment, and as shown in Table 3, lactobacillus plantarum SDJ09 has higher survival rate and shows excellent acid and gall salt resistance compared with control bacteria LGG.
TABLE 3 acid and bile salt resistance Properties of Lactobacillus plantarum SDJ09
4.3 in vitro simulated gastrointestinal fluids
The gastrointestinal fluids were simulated using an in vitro static digestion model, 3g/L pepsin in PBS (ph=3) and 1.0g/L trypsin in PBS (ph=8) and treated with 0.22 μm filters to sterilize. On the basis, after lactobacillus in simulated gastric fluid is subjected to stationary culture for 3 hours at 37 ℃, 1mL of the mixture is taken and added into 9mL of simulated gastrointestinal fluid, after continuous culture for 8 hours, gradient dilution coating is carried out, the survival rate is measured according to the number of viable bacteria on a plate before and after treatment, and the result is shown in Table 4, the survival rate of lactobacillus plantarum SDJ09 in simulated in vitro gastrointestinal fluid is higher than that of LGG, and the simulated gastric fluid has good in vitro resistance characteristics.
TABLE 4 in vitro simulated gastrointestinal fluid Properties of Lactobacillus plantarum SDJ09
4.4 bacteriostatic Capacity of Strain metabolite
The bacteriostatic ability of the metabolites of the strain is measured by adopting an oxford cup method, and the concentration of the strain is adjusted to 10 by PBS (phosphate buffer solution) for indicating the escherichia coli and staphylococcus aureus of the strain 8 CFU/mL is evenly coated on an LB plate, a culture solution after 24h of lactobacillus fermentation is taken, 8000r/min is centrifuged for 10min, supernatant fluid is taken to be treated by a 0.22 mu m filter membrane, 100 mu L of the supernatant fluid is absorbed into an oxford cup and is cultured for 24h, a bacteriostasis ring is measured, and the bacteriostasis effect is evaluated according to the diameter of the bacteriostasis ring. The results are shown in Table 5, and the lactobacillus plantarum SDJ09 metabolite has good antibacterial capability on the bacteria inhibition zone diameter of escherichia coli and staphylococcus aureus of more than 10 mm.
TABLE 5 bacteriostatic Capacity of Lactobacillus plantarum metabolites
4.5 antibiotic sensitivity of Lactobacillus plantarum SDJ09
The drug sensitivity test of lactobacillus adopts a drug sensitive paper agar diffusion method (K-B method), fresh thalli are centrifuged for 10min at 4 ℃ and 8000r/min, and the supernatant is discarded, and the thalli are collected. Resuspension with PBS, adjust the concentration to 10 7 CFU/mL, dividing the MRS solid culture medium into regions, marking, sucking 200 mu L of the solid culture medium, coating the solid culture medium on the MRS solid culture medium, placing the antibiotic drug sensitive tablet on the surface of a flat plate full of thalli, culturing for 48h at 37 ℃, observing a bacteriostasis ring and measuring the diameter of the drug sensitive ring. The experimental results are shown in Table 6, and lactobacillus plantarum SDJ09 is sensitive or intermediate to 8 antibiotics and has certain safety.
TABLE 6 antibiotic sensitivity of Lactobacillus plantarum SDJ09
5. Effect of different components of Lactobacillus plantarum SDJ09 on lipid accumulation in 3T3-L1adipocytes
5.1 preparation of samples
Preparation of cell-free extract (CFE): lactobacillus plantarum SDJ09 is cultured in MRS culture medium for 24h, centrifuged for 10min at 4deg.C and 8000r/min, washed twice with PBS, resuspended in distilled water, and OD adjusted 600 To 0.5+/-0.02, carrying out ice bath ultrasonic treatment for 30min (200W, 5s for work and 5s for interval), centrifuging, taking the supernatant, and carrying out freeze-drying treatment.
Preparation of metabolites (CM): activating lactobacillus plantarum SDJ09, inoculating into MRS liquid culture medium at 2% inoculum size, standing at 37deg.C for 24 hr, centrifuging at 4deg.C at 8000r/min for 10min, washing twice with sterile PBS, and regulating strain concentration with serum-free DMEM to 1×10 8 And (3) carrying out stationary culture for 2h at 37 ℃ by CFU/mL, centrifuging for 10min at 8000r/min at 4 ℃, and taking supernatant to be treated by a 0.22 mu m filter membrane to obtain a lactobacillus metabolite sample.
Preparation of inactivated cells (HK): after culturing for 24 hoursLactobacillus plantarum SDJ09, washed twice with sterile PBS, resuspended in PBS to adjust OD 600 And sterilizing at 121deg.C for 15min to 0.5+ -0.02 to obtain heat-inactivated lactobacillus.
5.2 Effect of different components of Lactobacillus plantarum SDJ09 on lipid accumulation in 3T3-L1 cells
Inducing differentiation of 3T3-L1adipocytes by classical cocktail method (refer to "Effects of Bacillus Subtilis-Fermented White Sword Bean Extract on Adipogenesis and Lipolysis of T3-L1 adipoytes."), adding 10% fetal bovine serum DMEM culture solution and 10% fetal bovine serum DMEM culture medium (model group) containing three components of lactobacillus plantarum SDJ09 to mature adipocytes after inducing differentiation, respectively, continuously culturing for 24h, taking normally grown 3T3-L1 cells as a control group (NC), sucking out the culture solution, carefully washing 3 times by PBS, and respectively measuring oil red O staining and triglyceride content.
The oil red O staining of 3T3-L1adipocytes under different treatment conditions is shown in FIG. 4, with red being lipid droplets, purple being cytoplasm, wherein A is model group (CON), B is cell-free extract treatment group (CFE), C is metabolite treatment group (CM), and D is inactivated thallus treatment group (HK).
Determination of triglyceride content:
to each well of the treated cells, 100. Mu.L of RIPA cell lysate containing 10. Mu.L of PMSF was added, and after sufficient lysis on ice, the supernatant was centrifuged at 12000r/min for 10min, and the triglyceride content and the total protein were measured using a triglyceride kit and a BCA kit. As shown in FIG. 5, the three components of Lactobacillus plantarum SDJ09 were able to reduce triglyceride levels in 3T3-L1adipocytes.
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the design spirit of the present invention.
Claims (10)
1. Lactobacillus plantarum (Lactobacillus plantarum) SDJ09 with lipid lowering function, which has been deposited at the cantonese province microorganism strain collection at 1-14 of 2022 under the accession number GDMCC No:62211.
2. a formulation comprising the lactobacillus plantarum of claim 1.
3. The formulation of claim 2, comprising one or more of a viable bacteria, an inactivated bacteria, a metabolite, and a cell-free extract of the lactobacillus plantarum.
4. A formulation according to claim 3, wherein the viable bacteria are prepared by the following method:
inoculating the lactobacillus plantarum into MRS liquid culture medium for culture, and then regulating the strain concentration to 10 8 -10 9 CFU/mL.
5. The preparation according to claim 4, wherein the live bacteria are sterilized at high temperature to obtain inactivated bacteria; performing ultrasonic treatment on the living bacteria, and centrifuging to obtain supernatant to obtain a cell-free extract; centrifuging the living bacteria to obtain supernatant, and filtering to obtain the metabolite.
6. The formulation of claim 4, wherein the lactobacillus plantarum is inoculated in an amount of 2-3%; the culture conditions are as follows: culturing at 35-38deg.C for 24-36 hr.
7. Formulation according to claim 5, characterized in that the high-temperature sterilization is in particular: sterilizing at 110-150deg.C for 10-30min; the power of the ultrasonic treatment is 200-300W, and the time is 20-30min.
8. Use of a lactobacillus plantarum according to claim 1 or a formulation according to any of claims 2-7 for the preparation of a lipid lowering food, pharmaceutical or animal feed.
9. The use according to claim 8, wherein the lactobacillus plantarum or preparation exerts a lipid lowering effect by degrading cholesterol, inhibiting pancreatic lipase and lowering lipid accumulation in adipocytes.
10. A food, pharmaceutical or animal feed with lipid lowering function, characterized by comprising the lactobacillus plantarum of claim 1 or the formulation of any of claims 2-7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211609647.5A CN116179419A (en) | 2022-12-14 | 2022-12-14 | Lactobacillus plantarum with lipid-lowering function and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211609647.5A CN116179419A (en) | 2022-12-14 | 2022-12-14 | Lactobacillus plantarum with lipid-lowering function and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116179419A true CN116179419A (en) | 2023-05-30 |
Family
ID=86451402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211609647.5A Pending CN116179419A (en) | 2022-12-14 | 2022-12-14 | Lactobacillus plantarum with lipid-lowering function and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116179419A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180040894A (en) * | 2016-10-13 | 2018-04-23 | 건국대학교 산학협력단 | Novel Lactobacillus plantarum Lb41 strain and compositions for the prevention and treatment of obesity containing the same |
| CN108728382A (en) * | 2018-06-07 | 2018-11-02 | 四川大学 | One plant of tool norcholesterol and lactobacillus plantarum and its application for promoting enteron aisle short chain fatty acids generation ability |
| CN112111433A (en) * | 2020-09-30 | 2020-12-22 | 兰州大学 | Lactobacillus plantarum LZU-J-QA85 with acid-resistant and bile salt-resistant activities and application thereof |
| US20220372433A1 (en) * | 2021-05-21 | 2022-11-24 | Shenzhen Bgi Agriculture Application Institute | Lactobacillus plantarum hg-23 and application thereof |
-
2022
- 2022-12-14 CN CN202211609647.5A patent/CN116179419A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180040894A (en) * | 2016-10-13 | 2018-04-23 | 건국대학교 산학협력단 | Novel Lactobacillus plantarum Lb41 strain and compositions for the prevention and treatment of obesity containing the same |
| CN108728382A (en) * | 2018-06-07 | 2018-11-02 | 四川大学 | One plant of tool norcholesterol and lactobacillus plantarum and its application for promoting enteron aisle short chain fatty acids generation ability |
| CN112111433A (en) * | 2020-09-30 | 2020-12-22 | 兰州大学 | Lactobacillus plantarum LZU-J-QA85 with acid-resistant and bile salt-resistant activities and application thereof |
| US20220372433A1 (en) * | 2021-05-21 | 2022-11-24 | Shenzhen Bgi Agriculture Application Institute | Lactobacillus plantarum hg-23 and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113061543B (en) | Lactobacillus plantarum and application thereof | |
| CN109182207B (en) | Lactobacillus acidophilus La-SJLH001 with probiotic functions of regulating blood sugar level, cholesterol level and the like and application thereof | |
| CN108102959B (en) | Humanized lactobacillus plantarum ZY08 for reducing cholesterol and application thereof | |
| CN112877241B (en) | Human lactobacillus fermentum ZJUIDS06 and application thereof | |
| CN112143680B (en) | Lactobacillus paracasei ZJUIDS05 with antioxidant effect and application thereof | |
| CN111849810B (en) | Lactobacillus ZJuuiss 03 for antagonizing helicobacter pylori and application thereof | |
| CN114752529B (en) | Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof | |
| CN114642686B (en) | Composite probiotics and its functions of delaying senility and resisting oxidation | |
| CN112812999B (en) | Lactobacillus plantarum SLB01 with inhibition effect on enterobacter cloacae and derivative product and application thereof | |
| CN116396890B (en) | Lactobacillus plantarum ZJUIDS15 for preventing and treating colon cancer and application thereof | |
| CN108018248B (en) | Lactobacillus casei capable of regulating flora structural disorder caused by antibiotics | |
| CN117143767A (en) | Breast milk-derived fermented lactobacillus mucilaginosus MSJK0025 capable of regulating intestinal flora and application thereof | |
| CN109619184A (en) | Application of the lactobacillus plantarum CQPC02 in the food or drug of preparation prevention liver oxidative damage | |
| KR102251294B1 (en) | A composition for preventing, improving or treating alcoholic gastritis of the comprising heat-killed lactobacillus salivarius v133 as an active ingredient | |
| CN114990030A (en) | Lactobacillus acidophilus LA18 and application thereof in preparing product for regulating intestinal flora or immunoregulation | |
| CN116970539B (en) | Lactobacillus murine complex, composition and application thereof | |
| CN116747245B (en) | Application of bifidobacterium animalis subspecies lactis BX-245 in bacteriostasis and/or production of functional active substances | |
| CN114806953B (en) | Lactobacillus gasseri with effect of improving type 1 diabetes | |
| CN113528367A (en) | Bacillus coagulans with functions of preventing diarrhea and degrading cholesterol | |
| CN116948884A (en) | Lactobacillus delbrueckii subspecies with high biofilm formation and strong stress resistance and application thereof | |
| CN116622568A (en) | Lactobacillus harbini P1-1 and application thereof | |
| CN116179419A (en) | Lactobacillus plantarum with lipid-lowering function and application thereof | |
| CN112708577B (en) | Lactobacillus fermentum DALI02 with high intestinal adhesion and immunoregulation function and application thereof | |
| CN114395514B (en) | Lactobacillus acidophilus, microbial inoculum and application thereof | |
| CN117305150B (en) | Bifidobacterium animalis BLH1, direct vat set starter and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |